
The first analysis of real-world outcomes in patients with neovascular age-related macular degeneration treated with pegcetacoplan for geographic atrophy demonstrated similar safety seen in clinical trials, according to a study.
At the American Society of Retina Specialists meeting, Janani Singaravelu, MD, presented a retrospective, observational cohort study that included 1,451 eyes with geographic atrophy, 991 (68.2%) with non-neovascular AMD and 460 (31.8%) with neovascular AMD.
The mean follow-up time was 7.5 months after the initial pegcetacoplan injection. Approximately 84% of patients